Compare Ascendis Pharma A/S (ASND) vs ING Groep NV (ING) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs ING Groep NV — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while ING Groep NV trades at $32.15 (market cap $92.53B). The key difference: ING Groep NV is far larger — about 5.2× Ascendis Pharma A/S's market cap, and ING Groep NV pays a 3.91% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | ING | |
|---|---|---|
Market Cap | $17.74B | $92.53B |
Sector | Health | Financials |
52-Week High | $277.18 | $32.96 |
52-Week Low | $163.32 | $22.45 |
Enterprise Value | $18.11B | — |
Dividend Yield | — | 3.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
ING trades at $32.39, down 0.34% today, with a bullish technical outlook supported by moving averages. The company maintains strong profitability with a 27.84% net income margin and has beaten earnings expectations for three consecutive quarters. Recent developments include the launch of a global subscription banking model and a $0.88 dividend payment scheduled for May 2026.
The stock presents a compelling value opportunity with a P/E of 12.99 and strong analyst support (62.5% buy ratings). However, negative operating cash flow trends and exposure to European banking sector volatility represent key risks. Upside potential exists from continued earnings outperformance and strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →
